
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is experiencing promising growth in its US demand and market access, as evidenced by strong sales and a growing number of authorized treatment centers. Additionally, the company's T cell programming technologies show potential for expanding its therapeutic offerings and addressing previously challenging diseases. Furthermore, recent positive real-world evidence and swift UK launch suggest a strong and swift pace for market adoption, with potential for near-term changes to NCCN guidelines. These factors, along with a solid revenue guidance and promising revenue forecasts, point to a positive and potentially strong future for Autolus Therapeutics' stock.
Bears say
Autolus Therapeutics is facing a potential long-term obstacle with the expected data readouts for its various clinical trials not being until 2026 and 2027 and the company potentially expending significant resources and time to expand the label for its flagship product, Aucatzyl, into the pediatric ALL market. Further complicating matters, the company faces intense competition from established players in the CAR-T therapy market and a highly saturated market for multiple myeloma treatments. Additionally, there remains plenty of room for growth in the pediatric r/r ALL market, which could further delay any potential revenue growth.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares